30194-68-4

Usage

Uses

Used in Pharmaceutical Industry:
2-[4-(2-pyrimidinyl)-1-piperazinyl]ethanamine(SALTDATA: 3HCl) is used as a therapeutic agent for the treatment of mental health disorders such as depression, anxiety, and obsessive-compulsive disorder. Its application is based on its ability to enhance the levels of serotonin and norepinephrine in the brain, which helps in mood regulation and symptom alleviation.
The 3HCl in the compound's name signifies that it forms a salt with three molecules of hydrochloric acid, which can influence its solubility and other properties, making it an important pharmaceutical compound with significant therapeutic applications in mental health treatment.

Upstream product

• 33386-13-9 2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetonitrile 
• 574-98-1 2-(2-bromoethyl)isoindoline-1,3-dione 
• 20980-22-7 N-(2-pyridinyl)piperazine 
• 95847-91-9 2-(2-(4-(pyrimidin-2-yl)piperazin-1-yl)ethyl)isoindoline-1,3-dione 

Relevant academic research and scientific papers

Synthesis, biological evaluation, and molecular modeling studies of chiral chloroquine analogues as antimalarial agents

In a focused exploration, we designed, synthesized, and biologically evaluated chiral conjugated new chloroquine (CQ) analogues with substituted piperazines as antimalarial agents. In vitro as well as in vivo studies revealed that compound 7c showed potent activity (in vitro 50% inhibitory concentration, 56.98 nM for strain 3D7 and 97.76 nM for strain K1; selectivity index in vivo [up to at a dose of 12.5 mg/kg of body weight], 3,510) as a new lead antimalarial agent. Other compounds (compounds 6b, 6d, 7d, 7h, 8c, 8d, 9a, and 9c) also showed moderate activity against a CQ-sensitive strain (3D7) and superior activity against a CQ-resistant strain (K1) of Plasmodium falciparum. Furthermore, we carried out docking and three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of all in-house data sets (168 molecules) of chiral CQ analogues to explain the structure-activity relationships (SAR). Our new findings specify the significance of the H-bond interaction with the side chain of heme for biological activity. In addition, the 3D-QSAR study against the 3D7 strain indicated the favorable and unfavorable sites of CQ analogues for incorporating steric, hydrophobic, and electropositive groups to improve the antimalarial activity.

Further delineation of hydrophobic binding sites in dopamine D 2/D3 receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5, 6,7,8-tetrahydro-naphthalen-2-ol

Here we report a structure-activity relationship (SAR) study of analogues of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro- naphthalen-2-ol. Our SAR is focused on introduction of various substitutions in the piperazine ring of the hybrid template. The goal behind this study is to delineate the nature of the binding pocket for N-aryl substitution in the piperazine ring by observing the effect of various hydrophobic and other heteroaromatic substitutions on binding affinity (Ki), as measured with tritiated spiperone and HEK-293 cells expressing either D2 or D3 receptors. Functional activity of selected compounds was assessed with the GTPγS binding assay. Compound 8d was the most selective for the D3 receptor in the spiperone binding assay. An interesting similarity in binding affinity was observed between isoquinoline derivative D-301 and the 2-substituted pyridine derivative 8d, suggesting the importance of relative spatial relationships between the N-atom of the ligand and the molecular determinants of the binding pocket in D2/D3 receptors. Functional activity assays demonstrated high potency and selectivity of (+)-8a and (-)-28b (D2/D3 (ratio of EC50): 105 and 202, respectively) for the D3 receptor and both compounds were more selective compared to the reference drug ropinirole (D2/D3 (ratio of EC50): 29.5).

Synthesis and biological evaluation of novel T-type Ca2+ channel blockers

A small molecule library of piperazinylalkylisoxazole derivatives containing about 600 compounds was designed, synthesized and evaluated for blocking effects on T-type Ca2+ channel. Several ligands were identified to possess high inhibitory activity against the T-type Ca 2+ channel. The compound 21 with trifluoromethyl substituents at C3-position of phenyl group (R1) and C2- position of phenyl group (R2) showed the highest inhibitory activity with IC50 value of 1.02μM, which is comparable to that of mibefradil.

2-aminoalkylaminoquinolines as dopamine D4 ligands

Disclosed are compounds of the formula or the pharmaceutically acceptable salts thereof wherein: A represents an optionally substituted alkylene group of from 2-5 carbon atoms; W is COH or CH; Y and Z are nitrogen or CH; and R1, R2, R3, R4, R5, R6are defined herein. Pharmaceutical compositions and preparations containing such compounds are also provided. The invention further relates to the use of such compounds in the treatment of neuropsychological diseases such as schizophrenia and other central nervous system diseases.

2-AMINOALKYLAMINOQUINOLINES; DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS

Disclosed are compounds of the formula: STR1 or the pharmaceutically acceptable salts thereof wherein: R 1, R 2, and R 3 are as defined herein;R 6 is hydrogen or C. sub.1-C. sub.6 alkyl, andQ represents a substituted azacycloalkylalkyl group,which compounds are useful in treating psychotic disorders such as schizophrenia and other central nervous system diseases.

Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones

A series of nootropic compounds of the following formula: STR1 and its pharmaceutically acceptable acid addition salts, wherein: R2 is hydrogen, lower alkyl, aryl which is optimally substituted, or hetaryl; R7 is hydrogen or is combined with R9 as a fused benzo-ring; R8 is hydrogen or lower alkyl; and R9 is lower alkyl, or R9 can be combined with R8 to give a 2-pyrrolidinone, a phthalimide, or isoindolone ring system. Pharmacological testing demonstrates that the series possesses cognition and memory enhancing actions and/or mild CNS simulation.